We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.115 | 9.96% | 1.27 | 47,237 | 08:00:08 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 1.02 | 1.28 | 1.27 | 1.27 | 1.27 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Finance Services | -2.92M | -0.0070 | -1.81 | 4.81M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 08:08:01 | O | 36,000 | 1.2069 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 10/12/2024 | 14:36 | UK RNS | Immupharma PLC Holding(s) in Company |
| 04/12/2024 | 07:00 | UK RNS | Immupharma PLC Appointment of Company Secretary |
| 09/9/2024 | 15:46 | ALNC |  ImmuPharma narrows losses in first half as expenses fall |
| 09/9/2024 | 11:45 | ALNC | ImmuPharma obtains second warrant extension with Incanthera |
| 09/9/2024 | 06:01 | UK RNS | Immupharma PLC Extension of Warrants in Incanthera to 31 Mar 2025 |
| 09/9/2024 | 06:00 | UK RNS | Immupharma PLC Half-year Report |
| 06/8/2024 | 12:41 | UK RNS | Immupharma PLC Holding(s) in Company |
| 28/6/2024 | 11:17 | UK RNS | Immupharma PLC Result of AGM |
| 05/6/2024 | 15:32 | ALNC | EARNINGS AND TRADING: STV sees advertising upturn; Angle loss narrows |
| 05/6/2024 | 13:01 | UK RNS | Immupharma PLC Notice of AGM & Annual Report & Accounts |
Immupharma (IMM) Share Charts1 Year Immupharma Chart |
|
1 Month Immupharma Chart |
Intraday Immupharma Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 29/11/2024 | 12:58 | IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES | 38,723 |
| 10/10/2022 | 12:36 | Immupharma | - |
| 30/9/2022 | 07:08 | (IMM) ImmuPharma PLC boss excited by “blockbuster potential” of Lupuzor | 79 |
| 27/7/2022 | 13:08 | IMMUPHARMA - Let's Talk about the Negatives | 389 |
| 02/6/2021 | 11:03 | 'One To Watch' Immupharma | 8 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 08:08:02 | 1.21 | 36,000 | 434.48 | O |
| 08:01:29 | 1.27 | 618 | 7.85 | O |
| 08:01:18 | 1.21 | 10,000 | 120.69 | O |
| 08:00:08 | 1.27 | 619 | 7.86 | AT |
| 2024-12-12 15:23:52 | 1.10 | 367,042 | 4,037.46 | O |
| Top Posts |
|---|
Posted at 12/12/2024 08:20 by Immupharma Daily Update Immupharma Plc is listed in the Finance Services sector of the London Stock Exchange with ticker IMM. The last closing price for Immupharma was 1.16p.Immupharma currently has 416,440,000 shares in issue. The market capitalisation of Immupharma is £4,789,060. Immupharma has a price to earnings ratio (PE ratio) of -1.64. This morning IMM shares opened at - |
Posted at 26/11/2024 10:59 by kingston78 The company was in the money on the warrants of INC, and if exercised at that time and sold the shares in the market would have made a tidy profit. Instead, the company paid £75k to extend the time limit for those warrants exercisable at 19.5 p, but INC's shares have tanked today to 3.5 p. Those warrants are under the water, and the £75k paid is now completely sunk. What a disaster of the decision made by the CEO of IMM!Not only that he personally holds a lot of shares in INC so he has lost money there too, at least on paper. |
Posted at 15/8/2024 11:16 by colsmith It seems as Jane Austin wrote in Pride and Prejudice and paraphrasing:"It is a truth universally acknowledged that anyone who makes a future share price (direction) prediction may be both right and wrong, but that they will only ever highlight one of those conditions." Of course the algo driven trading knows where to put the price but for IMM this isn't at least for now much of a issue although it seems someone is keeping it in a range. PS agree with Nobby in 38701. |
Posted at 05/6/2024 06:59 by stockriser This is where future funding will come from .... ;-)GLA SR The warrant deeds (between the Company and the respective counter-parties - the holders of warrants) have been varied, such that the exercise price of the 2021 Warrants and 2022 Warrants is reduced from 11 pence and 5.5 pence respectively to 2 pence. The 2021 Warrants and 2022 Warrants will then be exercisable at the earlier of (i) the five day volume weighted average price of Ordinary Shares attaining 4 pence or (ii) 12 months following First Admission or (iii) a takeover offer is announced for the Company. The reduction in the warrant exercise prices was agreed with all the warrant holders and from the Company's perspective, there will be a higher probability of receiving additional funding from the exercise of these warrants as the share price appreciates and the warrants are 'in the money'. |
Posted at 03/6/2024 10:46 by lord loads of lolly Presumably today's sale of IMM's entire holding in Incanthera, netting c£1.5m is to fund the c7.3 million warrants at 9.5p before they expire on 6 September 2024?7.3m Incanthera warrants would cost them around £694k. Assuming Incanthera's share price holds at around 20p, IMM can double their money on the warrants overnight & still have around £800k left over. |
Posted at 06/3/2024 08:46 by sicilian_kan Outstanding RNS. Remember IMM is currently priced to go bust, despite holding significant assets and today it being confirmed that there are no current plans to raise equity and that future cash requirements are expected to be non dilutive from up front payments in new commercial deals with unpartnered assets. Active discussions / a bread range of discussions confirmed.Among the assets are: 1. Fully funded P3 trial for Lupuzor, which IMM has double digit tiered royalties on up to 17% and milestone payments, whilst retaining all non-US rights that they hope to partner on this year. The US only deal itself is worth more than the current market cap, let alone the ROW rights that they can sell. 2. They have the worldwide rights for Lupuzor in CIPD that can go straight into a P2/3 and which they hope to partner on. Again, any deal would dwarf the current market cap. Orphan drug status being submitted which again would provide a large boost to the share price even before a deal. 3. The worldwide rights for BioAMB, an anti-infective program that they also hope to partner on. Part 1 of new dose ranging study in animal model complete and no toxisity. Moving to Part 2. Intial partnering discussions have commenced. 4. IMM owns 10.8% (as well as 7.3m warrants) in Incanthera, which concluded a significant commercial skincare deal with part of the AS Watson Group. This is the world's largest international health and beauty retailer owning brands like Superdrug, The Perfume Shop and many others. Significant revenues and profitability are expected to commence for Incanthera in 2024. 5. Overheads reduced by more than 75% since the new business plan came in. All for a market cap of £4.7m. Yes, sub £5m market cap, with no funding needs, for double digit royalties in a fully funded P3 trial, 100% of ROW rights to sell for that trial, 100% of CIDP worldwide rights to sell for the same drug to go into P2/3 trial, 10.8% share of a company expected to generate revenues and profitability this year with a partnership with the world's largest international health and beauty retailer, anti-infective progress and partnership discussions having commenced, and overheads reduced by 75%. It is in my view one of the most undervalued companies on AIM. It should easily have a market cap of £20m in its current position, or around 5p. And that is before any deals are done. |
Posted at 08/2/2024 11:20 by lord loads of lolly nobby - agreed. Though as I posted on 6th Feb, assuming the trial still proceeds with Avion's full funding, I suspect IMM's share price will rise significantly at some stage within the next two years or so, closer to readout. This is less in McCarthy's hands now than at any time previously.In the unlikely event it met its endpoints, IMM's share price would go stratospheric. Otherwise, it's likely to be RIP IMM, IMHO. |
Posted at 06/2/2024 17:30 by lord loads of lolly Dr Biotech - interesting. I generally agree and am very sorry to hear about your niece.My only thought re: IMM is that many holders (myself included) are probably hanging on (or averaging down) on the basis the share price could well rise as we get closer to the next trial results. I suspect many doubt this latest trial will actually deliver the goods (assuming it even happens). However, there might still be a way of erasing current paper losses by hanging on, then selling into any pre-readout froth. Of course, there's still a danger that IMM runs out of money before then, or that the expected share price rise never materialises! Your thoughts? |
Posted at 28/1/2024 10:45 by lord loads of lolly Luzley - the current share price reflects consensus view on IMM’s prospects of a SUCCESSFUL trial. Not just its stage of development.Also, there’s a possibility IMM will run out of cash shortly, which would mean a fund raise & yet more dilution. Not hard to see why the share price is where it is currently. Though sentiment could change rapidly, either for better or worse. |
Posted at 04/8/2022 07:42 by mudbath Thanks for providing some balance, supernumerary and 1bond.So much more edifying than the trite "big plunge coming tomorrow morning" and "Tim is a disgrace!" contributions. The IMM share price might indeed weaken further . In this event, I would hope to benefit from taking a decent position. |
Posted at 12/5/2022 20:46 by mudbath The IMM share price moves as if on a snakes and ladders board where the trades(or dice)that should determine its ascent or descent apparently having no influence.Nevertheless, it is a great stock from which to extract a daily margin, as the MMs seem happy to part with the shares in the morning at 5.75p only to seek their return at 6p or above, after lunch. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
